{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:07:13Z","timestamp":1793275633164,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtho.2024.06.008","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T21:10:19Z","timestamp":1718399419000},"page":"1449-1459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study"],"prefix":"10.1016","volume":"19","author":[{"given":"Ross A.","family":"Soo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyanan","family":"Reungwetwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman Andres","family":"Perroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullas","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Fernando","family":"Tejado Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Donner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Alsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Huggenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Van Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.06.008_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2024.06.008_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"Arriagada","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2024.06.008_bib4","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non\u2011Small Cell Lung cancer V.1.2024.\u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed 24 January 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any wayNational Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-small Cell Lung Cancer. V.1.2024. https:\/\/www.nccn.org\/. [Accessed 24 January 2024]."},{"key":"10.1016\/j.jtho.2024.06.008_bib5","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.22.00051","volume":"40","author":"Pisters","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib6","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.06.008_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejca.2022.01.038","article-title":"A\u00a0population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands","volume":"165","author":"Ten Berge","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2024.06.008_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A\u00a0prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (Pioneer)","volume":"9","author":"Shi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jtho.2024.06.008_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221129464","article-title":"Prevalence and patterns of EGFR mutations in non-small cell lung cancer in the Middle East and North Africa","volume":"29","author":"Boustany","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.jtho.2024.06.008_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","article-title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study","volume":"19","author":"Zhong","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib12","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib13","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.06.008_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.06.008_bib16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3390\/ijms20061431","article-title":"Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new insights and future perspectives in this complex clinical scenario","volume":"20","author":"Russo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2024.06.008_bib18","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jtho.2024.06.008_bib19","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib20","doi-asserted-by":"crossref","first-page":"e899","DOI":"10.1093\/oncolo\/oyac167","article-title":"EGFR mutations and PD-L1 expression in early-stage non-small cell lung cancer: a real-world data from a Single Center in brazil","volume":"27","author":"Alves Pinto","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2024.06.008_bib21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2024.06.008_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984349","article-title":"Lung cancer in never smokers: tumor immunology and challenges for immunotherapy","volume":"13","author":"de Alencar","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.06.008_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220691","article-title":"Oncogenic driver mutations in Swiss never smoker patients with lung adenocarcinoma and correlation with clinicopathologic characteristics and outcome","volume":"14","author":"Grosse","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.06.008_bib24","first-page":"48","article-title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update","volume":"2","author":"Bethune","year":"2010","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtho.2024.06.008_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/JTO.0b013e31821667b0","article-title":"Epidermal growth factor receptor mutation status in Stage I lung adenocarcinoma with different image patterns","volume":"6","author":"Hsu","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2022.12.010","article-title":"Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: implications for adjuvant therapy","volume":"181","author":"Hondelink","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2024.06.008_bib27","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/1759-7714.12651","article-title":"EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: analysis based on large-scale data from China","volume":"9","author":"Pi","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2024.06.008_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2024.06.008_bib29","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/JTO.0000000000000041","article-title":"Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays","volume":"9","author":"Chiu","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib31","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1158\/1078-0432.CCR-07-1387","article-title":"Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method","volume":"13","author":"Pao","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.06.008_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17394-7","article-title":"Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer","volume":"12","author":"Shen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.06.008_bib33","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","article-title":"Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial","volume":"9","author":"He","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtho.2024.06.008_bib34","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.cllc.2018.04.004","article-title":"ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection","volume":"19","author":"Wu","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2024.06.008_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.06.008_bib36","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/cells10082157","article-title":"EGFR status assessment for better care of early stage non-small cell lung carcinoma: what is changing in the daily practice of pathologists?","volume":"10","author":"Hofman","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jtho.2024.06.008_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.909064","article-title":"Diagnostic-therapeutic pathway and outcomes of early stage NSCLC: a focus on EGFR testing in the real-world","volume":"12","author":"Pasello","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.lungcan.2021.05.025","article-title":"Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: expert panel recommendations","volume":"158","author":"G\u00f6ker","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.06.008_bib39","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.21037\/tlcr-22-527","article-title":"Expert consensus on perioperative treatment for non-small cell lung cancer","volume":"11","author":"Duan","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2024.06.008_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12094-019-02134-7","article-title":"Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer","volume":"22","author":"Majem","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I\u2013III non-metastatic non-small cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib42","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2024.06.008_bib43","article-title":"Adjuvant chemotherapy for resected early-stage non-small cell lung cancer","volume":"2015","author":"Burdett","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jtho.2024.06.008_bib44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.21037\/tlcr-20-780","article-title":"Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant\/ALK-rearranged non-small cell lung cancer","volume":"10","author":"Reyes","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtho.2024.06.008_bib45","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/curroncol30040280","article-title":"Immunotherapy in early-stage non-small cell lung cancer (NSCLC): current evidence and perspectives","volume":"30","author":"Lazzari","year":"2023","journal-title":"Curr Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424006191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424006191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:48:17Z","timestamp":1728010097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424006191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1556086424006191"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.06.008","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}